Diurnal Variation in PAI-1 Activity Predominantly Confined to the 4G-allele of the PAI-1 Gene

Summary

We examined the diurnal pattern in Plasminogen Activator Inhibitor-type 1 (PAI-1) activity and Plasminogen activator (t-PA) in relation to the 4G/5G-polymorphism in the promoter of the PAI-1 gene. The analyses were performed in the Arnhem Elderly Study, a populationbased study of 598 elderly. A single blood sample was drawn and the time of blood sampling was recorded (between 8 a. m. and 5.30 p. m.). Plasma PAI-1 activity was strongly associated with time of blood sampling, showing the highest values in the early morning. The diurnal pattern was clearly present in the 4G/4G (n = 184) and 4G/5G (n = 275) genotypes, but not in the 5G/5G-genotype (n = 139). T-PA antigen showed a weak diurnal variation, which did not differ across the variants of the 4G/5G-polymorphism. Our findings raise the hypothesis that 5G-homozygotic persons may be relatively protected from diurnal variation in the occurrence of coronary events.

Keywords

Fibrinolysis - diurnal variation - PAI-1 - t-PA - 4G/5G-polymorphism

• References

• 1 Elliott WJ. Cyclic and circadian variations in cardiovascular events. Am J Hypertens 2001; 14: 291S-5S.
• 2 Muller JE. Circadian variation in cardiovascular events. Am J Hypertens 1999; 12: 35S-42S.
• 3 Ridker PM, Manson JE, Buring JE, Muller JE, Hennekens CH. Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation 1990; 82: 897-902.
• 4 Grimaudo V, Hauert J, Bachmann F, Kruithof EK. Diurnal variation of the fibrinolytic system. Thromb Haemost 1988; 59: 495-9.
• 5 Kohler HP, Grant PJ. Mechanisms of disease: Plasminogen-activator inhibitor type 1 and coronary artery disease. New Engl J Med 2000; 342: 1792-801.
• 6 Sayer JW, Gutteridge C, Syndercombe CD, Wilkinson P, Timmis AD. Circadian activity of the endogenous fibrinolytic system in stable coronary artery disease: Effects of beta-adrenoreceptor blockers and angiotensinconverting enzyme inhibitors. J Am Coll Cardiol 1998; 32: 1962-8.
• 7 Irokawa M, Nishinaga M, Funayama H, Ikeda U, Shimada K. Effect of a change in the sleep/wake cycle on the diurnal variation of fibrinolytic parameters. J Thromb Thrombolysis 1998; 05: 165-8.
• 8 Andreotti F, Prevost R, Lupi A, Hamilton J, deBart AW, Huisman LM, Maseri A, Kluft C. Circadian patterns of plasma t-PA and PAI-1 antigen levels in patients with severe peripheral atherosclerosis. Fibrinolysis 1996; 10 Suppl. 2: 159-60.
• 9 Masuda T, Ogawa H, Miyao Y, Yu Q, Misumi I, Sakamoto T, Okubo H, Okumura K, Yasue H. Circadian variation in fibrinolytic activity in patients with variant angina. Br Heart J 1994; 71: 156-61.
• 10 Bridges AB, McLaren M, Scott NA, Pringle TH, McNeill GP, Belch JJ. Circadian variation of tissue plasminogen activator and its inhibitor, von Willebrand factor antigen, and prostacyclin stimulating factor in men with ischaemic heart disease. Br Heart J 1993; 69: 121-4.
• 11 Chandler WL, Mornin D, Whitten RO, Angleton P, Farin FM, Fritsche TR, Veith RC, Stratton JR. Insulin, cortisol and catecholamines do not regulate circadian variations in fibrinolytic activity. Thromb Res 1990; 58: 1-12.
• 12 Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989; 79: 101-6.
• 13 Andreotti F, Davies GJ, Hackett DR, Khan MI, De Bart AC, Aber VR, Maseri A, Kluft C. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol 1988; 62: 635-7.
• 14 Eriksson P, Kallin B, van ’t Hooft F, Båvenholm P, Hamsten A. Allelespecific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-5.
• 15 Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-45.
• 16 Boekholdt SM, Bijsterveld NR, Moons AHM, Levi M, Buller HR, Peters RJG. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction. Circulation 2001; 104: 3063-8.
• 17 Maemura K, de La Monte SM, Chin MT, Layne MD, Hsieh CM, Yet SF, Perrella MA, Lee ME. CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression. J Biol Chem 2000; 275: 36847-51.
• 18 Van den Hombergh CE, Schouten EG, van Staveren WA, van Amelsvoort LG, Kok FJ. Physical activities of noninstitutionalized Dutch elderly and characteristics of inactive elderly. Med Sci Sports Exerc 1995; 27: 334-9.
• 19 Margaglione M, Grandone E, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, d’Addedda M, DiMinno G. An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb Haemost 1997; 77: 605-6.
• 20 Koistinen HA, Dusserre E, Ebeling P, Vallier P, Koivisto VA, Vidal H. Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic and Type 2 diabetic subjects. Diabetes Metab Res Rev 2000; 16: 364-9.
• 21 Kono T, Morita H, Nishina T, Fujita M, Hirota Y, Kawamura K, Fujiwara A. Circadian variations of onset of acute myocardial infarction and efficacy of thrombolytic therapy. J Am Coll Cardiol 1996; 27: 774-8.
• 22 Kurnik PB. Circadian variation in the efficacy of tissue-type plasminogen activator. Circulation 1995; 91: 1341-6.
• 23 Van der Bom JG, Bots ML, Haverkate F, Kluft C, Grobbee DE. Diurnal variation of PAI-1 partly explained by 4G5Gpolymorphism. Haemostasis 2000; 30: 1-2. 37 (abstract).